GlassScriptPhysician profile
Jonathan Vernon Amos
NPI 1740660604
$3,942.13
in general payments reported to CMS, 2019-2025
26 companies · $916 in 2025
The $916 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $916 · 2023: $760 · 2024: $814 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.66 | 2021-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $586.71 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $409.66 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $356.02 | 2021-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $294.30 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $191.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.91 | 2022-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $114.79 | 2022-2025 | Acthar |
| Genentech USA, INC. | $103.18 | 2021-2023 | Actemra, Rituxan |
| Alexion Pharmaceuticals, INC. | $100.33 | 2022-2025 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $97.59 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $94.34 | 2022-2025 | Benlysta |
| Sobi, INC | $84.37 | 2021-2024 | |
| Lilly USA, LLC | $68.77 | 2021-2023 | Taltz |
| Horizon Therapeutics Plc | $60.74 | 2022-2023 | Krystexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $60.43 | 2024-2025 | |
| Organon LLC | $57.66 | 2022 | |
| Fresenius Kabi USA, LLC | $41.17 | 2023-2024 | Idacio, Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.91 | 2022-2023 | Cyltezo |
| Teva Pharmaceuticals USA, INC. | $36.87 | 2023-2024 | Truxima |
| Radius Health, INC. | $34.52 | 2025 | Tymlos |
| Hospira, INC. | $34.04 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $32.66 | 2022 | |
| Grifols USA, LLC | $29.49 | 2025 | Gamunex-C |
| Ani Pharmaceuticals, INC. | $22.53 | 2022 | |
| Scilex Pharmaceuticals INC. | $22.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.